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1932sudden cardiac arrest during MSHSL [Minnesota State High
School League] practice or games and lived, nor does it include
SCDs that occurred outside the auspices of MSHSL” (1).
Dr. Weinrauch implies that we should be counting deaths that
occur “outside of the few hours per week of sports exposure.” We
are unaware of data to suggest that, when not participating in
sports, high school athletes are at greater risk than their nonathlete
peers. The data from Corrado et al. (2) found that >90% of SCDs
in athletes occurred during sports and nearly 90% of deaths in
nonathletes were during sedentary activities. Counting deaths
outside of high school sports suggests that we apply electrocar-
diographic (ECG) screening to all students and view it from a
public health perspective. It is important to recall that many more
students and athletes die of causes unrelated to SCD (e.g., alcohol
and drug, motor vehicle accidents, and suicide) than of SCD.
From a public health perspective, it may be wiser to put more
capital into preventing those noncardiac causes of death through
thorough pre-participation evaluations (PPEs) and developing
emergency action plans with automatic external deﬁbrillators for
each school.
The denominator in this study is likely the most accurate
reﬂection of MSHSL athlete-years available. The unduplicated
athlete number is a summation of 19 years of all athletes. To be
included in this pool, an athlete must be cleared to participate with
a PPE using a standardized form that was introduced in 1992,
coincidentally the ﬁrst year that the unduplicated athlete number
was tracked by the MSHSL, and make the limited rosters of one of
the high school teams (freshman, B squad, junior varsity, or var-
sity). In a Venn diagram, there would be an undetermined overlap
between the sets of athletes in organized programs and athletes in
MSHSL programs. Dr. Weinrauch notes that some students may
have had a PPE and made a team, but then not participated;
we agree that that is possible, but likely rare. Previous studies of
Minnesota athletes by Maron et al. (3,4) and highlighted by
Dr. Weinrauch all used participant estimates for the denominators.
We concur with Dr. Weinrauch’s call for improved databases to
accurately track both the numerator and denominator with regard
to sudden cardiac arrest in young athletes, but the numerator and
denominator must be concordant to reﬂect the actual population at
risk. We would suggest that the issue be addressed with respect to
age groups (6 to 10, 11 to 14, 15 to 18, 19 to 25, and 26 to 35 years
of age), sex, ethnicity, and intensity of activity. Using electronic
versions of the PPE tied to injury tracking programs may make
large-scale studies of interventions such as electrocardiography for
cardiac screening plausible. Rather than jumping headlong into
ECG screening of all athletes with the accompanying ramiﬁcations
of false positives and negatives, it would seem prudent to uniformly
use standardized PPEs across the country and to begin to study the
outcomes in athletes with and without ECG screening.
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It is my pleasure to respond to Dr. Weinrauch’s letter concerning
our paper (1) because it provides a unique opportunity to highlight
some of the broader issues of concern to the sports cardiology
community.
Dr. Weinrauch is not alone in his call for a meaningful, well-
conducted sudden cardiac death (SCD) registry because many ac-
ademicians share his concerns related to methodology, choice of
correct numerators and denominators in the SCD rate equation,
and question of efﬁcacy of electrocardiographic screening in youths
and young athletes in the United States (2). To address these
concerns, a working group convened in April 2010 by the National
Heart, Lung, and Blood Institute (NHLBI) concluded that “this
(ECG) debate will continue unresolved until additional, compel-
ling evidence is provided that either supports or refutes the utility of
screening for SCD in the young” (1). The group called for an
aggressive research agenda, including a prospective registry of SCD
in the young.
Although cardiologists have deﬁned standard outcome measures
for certain interventions (3), the greater sports cardiology com-
munity has not yet done the same for athletic populations. As a
result, comparisons among studies are problematic, and debate
ensues. Some studies deﬁne SCD as death occurring during or
within 1 h of exercise in a competitive athlete. Using this deﬁ-
nition, Danish investigators reported an SCD incidence of 1.21
per 100,000 person-years in athletes, markedly lower compared
with 3.76 per 100,000 person-years among the general population
12 to 35 years of age (4). Alternatively, some studies include
sudden cardiac arrests (SCAs) and resuscitated events. In King
County, Washington, investigators reported an overall SCA/SCD
rate of 2.28/100,000 person-years in the general population of
young people 0 to 35 years of age (5). Just 25% of cases occurred
during or within 1 h of exercise, suggesting that re-calculation of
the SCD rate would bring the ﬁgure closer to, if not lower than,
the Danish numbers. Well-deﬁned uniform metrics in athletic
populations would be of great beneﬁt to the sports medicine and
sports cardiology communities and would allow for greater
consensus, proper clinical trial design, and the development of
proper guidelines. Although resuscitated SCAs certainly qualify as
adverse cardiac events, they may not be suitable for the numerator
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1933of the SCD equation because death did not actually occur.
Marathon race directors have adopted this approach (6), which
has had useful practical application in advising risk of participa-
tion, while assisting in event preparation and the best allocation of
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Metoprolol,
But Which Metoprolol?
Effect on Inappropriate
Cardioverter-Deﬁbrillator TherapyRuwald et al. (1) studied the beneﬁt of carvedilol versus meto-
prolol for inappropriate antitachycardia pacing (ATP), using
data from the MADIT-CRT (Multicenter Automatic Deﬁ-
brillator Implantation with Cardiac Resynchronization Ther-
apy) trial. In a following editorial comment, Raitt (2) discusses
further the issue of inappropriate ATP. What is most surprising
is that neither Ruwald et al. (1) nor Raitt (2) specify metoprolol
as the tartrate or the succinate form. This failure to indicate
the rapid- or delayed-release forms of the medication whenconcluding superiority in favor of carvedilol has to be of concern
to the reader. The major clinical trial of metoprolol, MERIT-
HF (Metoprolol CR/XL Randomised Intervention Trial in
Congestive Heart Failure), which showed a signiﬁcantly decreased
all-cause mortality in their heart failure patients, speciﬁcally used
metoprolol succinate (3). When carvedilol and metoprolol were
compared in the COMET (Carvedilol or Metoprolol European
Trial) using metoprolol tartrate (target dose, 50 mg twice daily)
versus carvedilol (target dose, 25 mg twice daily), the composite
endpoint of mortality and all-cause admissions was not signiﬁ-
cantly different for the 2 medications, although the authors
considered that there was a suggestion of carvedilol superiority (4).
Obviously, the comparator in the current papers under consider-
ation (1,2) ideally should have been the succinate form of meto-
prolol, as in MERIT-HF (3).*Thomas F. Whayne, Jr, MD, PhD
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But Which Metoprolol?
Effect on Inappropriate
Cardioverter-Deﬁbrillator TherapyWe thank Dr. Whayne for the interest and questions that he had
with regard to our recently published results from the MADIT-
CRT (Multicenter Automatic Deﬁbrillator Implantation With
Cardiac Resynchronization Therapy) trial (1) and accompanying
editorial (2).
